The Food and Drug Administration (FDA) has given a green signal to Allergan's AGN Botox. It would be used as a treatment for the adult urinary incontinence, which results from a neurological disorder.

The approval means, from now, the drug would be allowed in the US. It would be given in the form of injection to those who have overactive bladders with neurologic conditions such as multiple sclerosis, spinal sclerosis and spinal cord injury. The injection would help the affected patient to get his muscles relaxed.

It is said that the sale of this beauty drug could reach $40 million in 2017. Scott Whitcup, Allergan’s Chief Scientific Officer and Executive Vice President for research and development quoted, “This approval of Botox is an important milestone in Allergan’s commitment to develop and make available novel treatment options for urologists and their patients”.

It should also be put in to notice that the 200-unit Botox injection would only be given to the patients if previous treatments of oral medications would get fail. As per the Allergan, there are nearly 340,000 individuals in the U. S, who suffer from this problem and more than half of them do not get benefitted from oral medications.